Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here's an excellent post from Yahoo!
"Brilliant deal and huge milestone for Sorrento today to enter gene-encoded therapeutics by acquiring SmartPharm. In a nutshell, SmartPharm's gene-encoded technology makes Sorrento's antibody therapeutics, such as STI-1499, far more effective and long-lasting by eliminating the problems of conventional gene therapies using so called "viral vectors" for delivery, which adds complexity in manufacturing and may incur unexpected immune responses. This is an even bigger and far more meaningful deal than COVI-TRACE because it benefits Sorrento's entire pipeline of antibody therapeutics.
STI-1499 + gene-encoded delivery = STI-2020dna. Take just 1 shot and it's good for a long time to prevent/clear out COVID from your body and it has a huge advantage over vaccines when it comes to dealing with virus mutation. Vaccines are also far less effective for elderly people who have weaker immune responses. Based on this amazing synergy of best antibody + best delivery technology, as well as promising preclinical trial data, I have a feeling that STI-2020dna (and other COVID antibodies) will cruise through clinical trials with expected safety and efficacy, meaning, the CURE."
Sorrento's 1499 has had 100% efficacy in the most predictive animal model. Combining it with SmartPharms technology means a persons own body beomes a 1499 antibody factory! Animal trials have already shown good results. This will soon be in clinical trials!
Combining SmartPharm's technology with Sorrento antibodies is genius. Here is what SmartPharm says about its technology.
Key Summary
*Vaccines are limited in addressing the current coronavirus pandemic
*Vaccines are dependent on the condition of the recipient’s immune system and infectivity status; additional preventative approaches are likely to be needed.
*Monoclonal antibodies offer a window of protection. Antibodies given to people that neutralize SARS-CoV-2 can provide a “window of protection” against coronavirus infection regardless of the status of the recipient’s immune system or infectivity. Antibodies have successfully been used to protect people from infectious viruses.
The use of monoclonal antibodies as a prophylaxis for COVID-19 is a limited option
Their high cost and typical requirements for intravenous administration make it unlikely they can be given to millions of people for population protection.
SmartPharm's Gene Mabs™ offers a creative solution
SmartPharm’s Gene Mab™ platform combines a novel DNA plasmid with long duration of expression and a safe, effective delivery system for use with standard hypodermic injection. Giving people a DNA plasmid injection to the muscle that can produce the needed neutralizing antibody in their bodies over a matter of weeks or months potentially offers a more scalable and cost-effective way of providing population protection against COVID-19 than directly giving them monoclonal antibodies.
Limitations of vaccines for protection against COVID-19
One of the key countermeasures under development to protect people from SARS-Cov-2 (the virus that causes COVID-19 infection) is vaccination. Vaccines have the benefit of being widely distributable as a means of protection populations from disease. However, they have some key limitations for COVID-19 prevention. One of the main issues, is that they are dependent on the recipient’s immune system to develop a protective response against the coronavirus. Not everyone’s immune system has the same ability to mount a protective response after vaccination. This is particularly true of the elderly, who are one of the high-risk groups for COVID-19. Other groups that have trouble mounting a good immune response are infants, people who are immunosuppressed (like organ transplant patients) and people with certain diseases, like people with heart or lung disease. A second issue with using vaccines to create immune protection, is that establishing immunity takes time. It can be weeks before the level of immune response is adequate in some diseases. It is unknown how long it will take for people to mount protective immunity against SARS-CoV-2; successful vaccination may ultimately require multiple injections over time, like vaccines against hepatitis or human papillomavirus. Another limitation of infectious disease vaccines is that they are typically intended for protecting healthy people and do not have much effect if someone is already infected.
Sorrento has claimed to have the very best anti-Covid antibody. First this claim was based on what happenened in a petri dish. Now it is based on what happened in the most predictive animal model. The results of this study have been given to the federal government and will be published as soon as possible in a scientific journal. Now this low dose 100% effective antibody is ready to go into hospitalized patients.
Antibodies can be only partially effective and require large expensive doses. Sorrento has an antibody that has been 100% effective against the highly contagious D614G mutant strain at a low dose. This will be a treatment game-changer! This is very exciting good news. Along with Sorrento's rapid high accuracy tests it can open up the economy.
100% neutralizing effect at one-fifth the dosage of other antibodies!
THE BEST POSSIBLE RESULTS AT A LOWER COST. The results have been given to the Federal government and "will be published AS SOON AS POSSIBLE IN A SCIENTIFIC JOURNAL." Great news!
I'm a value investor. The CFO firing does not affect the value of Sorrento's great pipeline. Shorters may try to take advantage which creates a buying opportunity for longs. Portfolio news tomorrow could squeeze the shorts! We'll see. I'm adding not selling!
"Sorrento now is gathering the materials to apply for an emergency use authorization (EUA) for Covi-Trace, said Mark Brunswick, senior vice president of regulatory affairs. Marketing would commence after the FDA gives the green light, although technically it could start as soon as the application is submitted.
“We don’t want to go out there with a test that we think is great, and the FDA says, ‘no way,’ and then we have to stop testing,” Brunswick told BioWorld. “We are in the process of collecting the patient samples; we’ll be running those tests, and we hope to submit the EUA [request] by the middle-of-August, end-of-August time frame while we are gearing up the production of the kits. And when we are geared up, we should have [an answer] back from the FDA as to whether we are good to go or not. But the FDA is on its own time.”
Moderna had a market cap well over $30 billion. SRNE has a $3 billion market cap as it works on 3 vaccines, 2 antibodies , 1 anti-cytokine storm oral drug and an 8 minute antiboby test and a 28 minute virus spit test. Moderna's vaccine apparently has some real problems ... but Sorrento has a chance to get both tests on the market very soon and all its drugs, vaccines and antibodies into the clinic in a few weeks. If your looking for share price increase SRNE looks very good to me!
Sorrento’s COVI-TRACE doesn’t need a lab and has an exclusive agreement. Big moves are coming.
https://stocktwits.com/idontbuyit/message/236808658
Many of these events will occur in the next 2-3 weeks.I'm holding!
1. COVI-TRACK 8 minute antibody test kit approval and marketing partnership
2. COVI-TRACE 30 minute virus saliva test kit approval
3. Celularity reports good interim phase 1/2 results (Sorrento owns 25%)
4. COVI-GUARD single antibody enters clinic
5. COVI-SHIELD triple antibody enters clinic
6. T-VIVA-19 vaccine enters clinic
7. Abivirtinib cytokine storm trial phase 2 enters clinic
8. Preclinical, peer reviewed data publication on STI-1499 and STI-4398 from UTMB, Dr. Slobodan Paessler (anytime now).
9. Sorrento/SmartPharm antibody vaccine enters clinic
10. Federal grants $500+ million
11. PSS decides to agree to $1.2 billion out of court settlement
12. Analysts upgrade from current $24 price target (DONE.) Now $30 and rises as each catalyst is announced)
Here are the new job openings at Sorrento. A lot is happening!
Careers at Sorrento Therapeutics, Inc
Sorrento Therapeutics, Inc. is an Equal Opportunity Employer and offers candidates an attractive salary and comprehensive benefits package that includes stock options, medical, dental, life and disability insurance, 401k and paid holidays.
Open Positions
Business Operations AssociateSan Diego, California
Clinical Scientist/Technician (2 openings)San Diego, California
Corporate Account Director - ScilexPalo Alto, California
Director, Analytical and BioassaySan Diego, California
Director, Sales Operations - ScilexPalo Alto, California
Document Control SpecialistSan Diego, California
Facilities Operations AssociateSan Diego, California
Financial Analyst - InternSan Diego, California
Manager, Antibody Upstream ManufacturingSan Diego, California
Manager, Downstream ManufacturingSan Diego, California
Manager, IP & Legal OperationsSan Diego, California
Manager, Quality Assurance (2 Openings)San Diego, California
Manufacturing Associate IISan Diego, California
Manufacturing Technician ISan Diego, California
Materials AssociateSan Diego, California
NetSuite ConsultantSan Diego, California
Office Manager and Document Control Administrator, Sofusa®Sandy Springs,, Georgia
Process Development and Manufacturing Associate - Cell Therapy (3 Openings)San Diego, California
Process Development and Manufacturing Associate - Gene Therapy Vector (2 Openings)San Diego, California
Project Coordinator - BioservSan Diego, California
Project Coordinator - Diagnostics LabSan Diego, California
Public Relations/Investor Relations ManagerSan Diego, California
Quality Assurance EngineerSandy Springs,, Georgia
Quality Control Associate I/II/III (2 Openings)San Diego, California
Quality Control Microbiology AssociateSan Diego, California
Regulatory Affairs AssociateSan Diego, California
Research AssociateSan Diego, California
Research Associate/Senior Research Associate, ImmunologySan Diego, California
ScientistSan Diego, California
ScientistSan Diego, California
ScientistSan Diego, California
ScientistSan Diego, California
Scientist - Cell Culture DevelopmentSan Diego, California
Scientist, CAR-TSan Diego, California
Scientist, in VivoSan Diego, California
Scientist/ChemistSan Diego, California
Scientist/Senior ScientistSan Diego, California
Senior Manufacturing Associate, Downstream (2 Openings)San Diego, California
Senior Project CoordinatorSan Diego, California
Senior ScientistSan Diego, California
Supervisor, Downstream ManufacturingSan Diego, California
Supply Chain ManagerSan Diego, California
Upstream Process Development & Manufacturing AssociateSan Diego, California
Validation SpecialistSan Diego, California
Validations Manager / EngineerSan Diego, California
Warehouse Specialist
Here's a list of Sorrento product name trademarks. A lot of news coming.
https://uspto.report/company/Sorrento-Therapeutics-Inc
Be calm and carry on! This company has a great Covid Strategy.
First two rapid accurate tests.
Then the oral drug to calm the cytokine storm .
Followed by safe and powerful antibodies to attack the virus.
And finally 4 or 5 vaccine candidates to prevent infection.
WHEN OTHERS FAIL THEY WILL BE THERE WITH "THE BEST-IN-CLASS " TO DOMINATE THE MARKET. Think how 93% effective Shingrex dominates the shingles market where the SOC was about 55% effective.
And Sorrento has blockbuster non-opioid pain and cancer drugs worth more than the Covid program in the long run. Trust the science!
Anyone who thought Sorrento would have the FIRST vaccine were fooling themself. Sorrento is aiming to have the BEST vaccine! And they are aiming to have the BEST antibody therapeutic. And they are aiming to have the BEST tests. They are also aiming to have the BEST non-opioid pain portfolio and the BEST cancer drugs. It is the BEST tests, vaccines, therapeutics and drugs which will become the sales leaders.
One analyst has said that their non-opioid pain portfolio alone is worth a $20 share price. What are all parts of the company worth? My quess is $100
+ ....go to the company website and have a look at the entire portfolio .
Good job! Now let's see the news start to flow.
28 Reasons why my price target is $100+
1. PSS lawsuit worth $1.2 Billion+ potential
2. BARDA funding, other government funding
3.CYNK-001 NK FDA Phase 1/Phase 2 Trial data with Celularity (Sorrento has 25% stake)
4. STI-4398 (COVIDTRAP) FDA Phase 1 clinical trial
5. STI-1499 (COVIGUARD)FDA IND approval
6. COVISHIELD(Therapeutic cocktail in partnership with Mt. Sinai Hospital) FDA IND application
7. Preclinical, peer reviewed data publication on STI-1499 and STI-4398 from UTMB, Dr. Slobodan Paessler (anytime now).
8. I-Cell COVID 19 Vaccine IND approval
9. Sorrento and SmartPharm gene encoded vaccine IND application
10. Sorrento and MabPharma ACE MAB IND approval
11. Phase 1 trial data of CD 38 for Amyloidosis
12. SP-102 phase 3 results
13. CD38 lymphoma IND
14. RTX arthritis news
15. RTX knee pain news
16. RTX cancer pain news
17. RTX ARDS treatment
18. Scilex potential IPO
19. FDA approval of COVI-TRACK
20. Sales begin for COVI-TRACK
21. Several cancer trials with first-in-class DAR-T are coming
22. Abivirtinib phase 2 in Covid begins in August
23. Water soluble CBD partnership
24. Covid T-VIVA-19 Vaccine enters clinic.
25. COVI-TRACE saliva test enters clinic.
26. COVI-TRACE gains approval
27. SOFUSA delivery phase 1b cancer trial
28. Analysts target prices are increasing
Sorrento is increasingly being seen as a leader in Covid, non-opioid pain and cancer technologies. It is a small pharma with a large pharma portfolio. There's a lot of room for partnerships and growing value for a buyout. Big pharmas with emptying portfolios will be attracted by a fistful of potential blockbusters!
Sorrento's 11 COVID programs make it the industry leader. It also has blockbuster non-opioid pain and cancer drug portfolios. Potential catalysts include...
1. PSS lawsuit worth $1.2 Billion+ potential
2. BARDA funding, other government funding
3.CYNK-001 NK FDA Phase 1/Phase 2 Trial data with Celularity (Sorrento has 25% stake)
4. STI-4398 (COVIDTRAP) FDA Phase 1 clinical trial
5. STI-1499 (COVIGUARD)FDA IND approval
6. COVISHIELD(Therapeutic cocktail in partnership with Mt. Sinai Hospital) FDA IND application
7. Preclinical, peer reviewed data publication on STI-1499 and STI-4398 from UTMB, Dr. Slobodan Paessler (anytime now).
8. I-Cell COVID 19 Vaccine IND approval
9. Sorrento and SmartPharm gene encoded vaccine IND application
10. Sorrento and MabPharma ACE MAB IND approval
11. Phase 1 trial data of CD 38 for Amyloidosis
12. SP-102 phase 3 results
13. CD38 lymphoma IND
14. RTX arthritis news
15. RTX knee pain news
16. RTX cancer pain news
17. RTX ARDS treatment
18. Scilex potential IPO
19. FDA approval of COVI-TRACK
20. Sales begin for COVI-TRACK
21. Several cancer trials with first-in-class DAR-T are coming
22. Abivirtinib phase 2 in Covid begins in August
23. Water soluble CBD partnership
24. Covid T-VIVA-19 Vaccine enters clinic.
25. COVI-TRACE saliva test enters clinic.
26. COVI-TRACE gains approval
27. SOFUSA delivery phase 1b cancer trial
28. Analysts target prices are increasing
Sorrento is increasingly being seen as a leader in Covid, non-opioid pain and cancer technologies. It is a small pharma with a large pharma portfolio. There's a lot of room for partnerships and growing value for a buyout. Big pharmas with emptying portfolios will be attracted by a fistful of potential blockbusters!
Interesting BOOM CALENDAR. Includes big pain and cancer news as well as Covid.
https://www.biotechboom.org/post/sorrento-therapeutics-boom-calendar?postId=5f2d191a00ac550017541b00
WHAT WOULD JUST HALF OF THESE EVENTS OCCURING IN AUGUST DO TO THE SHARE PRICE?
1. COVI-TRACK 8 minute antibody test kit approval and marketing partnership
2. COVI-TRACE 30 minute virus saliva test kit approval
3. Celularity reports good interim phase 1/2 results (Sorrento owns 25%)
4. COVI-GUARD single antibody enters clinic
5. COVI-SHIELD triple antibody enters clinic
6. T-VIVA-19 vaccine enters clinic
7. Abivirtinib cytokine storm trial phase 2 enters clinic
8. Preclinical, peer reviewed data publication on STI-1499 and STI-4398 from UTMB, Dr. Slobodan Paessler (anytime now).
9. Sorrento/SmartPharm antibody vaccine enters clinic
10. Federal grants $500+ million
11. PSS decides to agree to $1.2 billion out of court settlement
12. Analysts upgrade from current $24 price target (DONE.) Now $30 and rises as each catalyst is announced)
Preclinical, peer reviewed data publication on STI-1499 and STI-4398 from UTMB, Dr. Slobodan Paessler (anytime now).
What will the share price be if even HALF these events occur in the next four weeks? Only Sorrento has 11 shots on Covid goal!
1. COVI-TRACK 8 minute antibody test kit approval and marketing partnership
2. COVI-TRACE 30 minute virus saliva test kit approval
3. Celularity reports good interim phase 1/2 results (Sorrento owns 25%)
4. COVI-GUARD single antibody enters clinic
5. COVI-SHIELD triple antibody enters clinic
6. T-VIVA-19 vaccine enters clinic
7. Abivirtinib cytokine storm trial phase 2 enters clinic
8. Sorrento/SmartPharm antibody vaccine enters clinic
9. Federal grants $500+ million
10. Analysts upgrade from current $24 price target (DONE. Now $30 and rises as each catalyst is announced)
Sorrento is the only company with 11 Covid technologies. It is debt free and insiders own 34%. And there are a ton of potential catalysts coming over the next 3-4 weeks.
1. PSS lawsuit worth $1.2 Billion+ potential
2. BARDA funding, other government funding
3.CYNK-001 NK FDA Phase 1/Phase 2 Trial data with Celularity (Sorrento has 25% stake)
4. STI-4398 (COVIDTRAP) FDA Phase 1 clinical trial data
5. STI-1499 (COVIGUARD)FDA IND approval
6. COVISHIELD(Therapeutic cocktail in partnership with Mt. Sinai Hospital) FDA IND application
7. Preclinical, peer reviewed data publication on STI-1499 and STI-4398 from UTMB, Dr. Slobodan Paessler (anytime now).
8. I-Cell COVID 19 Vaccine IND approval
9. Sorrento and SmartPharm gene encoded vaccine IND application
10. Sorrento and MabPharma ACE MAB IND approval
11. Phase 1 trial data of CD 38 for Amyloidosis
12. SP-102 phase 3 results
13. CD38 lymphoma IND
14. RTX arthritis news
15. RTX knee pain news
16. RTX cancer pain news
17. RTX ARDS treatment
18. Scilex potential IPO
19. FDA approval of COVI-TRACK
20. Sales begin for COVI-TRACK
21. Several cancer trials with first-in-class DAR-T are coming
22. Abivirtinib phase 2 in Covid begins in August
23. Water soluble CBD partnership
24. Covid T-VIVA-19 Vaccine enters clinic.
25. Covid-Trace enters clinic.
Sorrento is increasingly being seen as a leader in Covid, non-opioid pain and cancer technologies. It is a small pharma with a large pharma portfolio. There's a lot of room for partnerships and growing value for a buyout. Big pharmas with emptying portfolios will be attracted by a fistful of potential blockbusters!
You should do your own due diligence before you buy any stock ! Here's a good place to begin with Sorrento. Excellent explanation of the Covid, non-opioid pain and cancer programs. There are several blockbusters in each program!
https://sorrentotherapeutics.com/research/pipeline/
Sorrento Therapeutics: Catalyst That Go Boom!
https://www.biotechboom.org/post/sorrento-therapeutics-catalyst-that-go-boom
“Now I cannot give you an exact date as to when COVI-TRACK will receive approval, but I can tell you this. If you are not in the invested when it is announced you will be chasing as this ticker will move, and it moves quick. Get in early as any day now news can hit the wire.
The second catalyst I want to cover is one that is very Important. This is the trial, that if successful, will make a SRNE take off to the likes of NVAX. Now STI-1499 "The Cure" is slated to start trials this month. Dr Ji mentioned at the Terrapin conference that he would be submitting the IND package in the very near future, and when he says that, he means Aug 14 at the latest...The FDA will not wait for the full 30 days to approve STI-1499 IND either. How do I know? Get this. The FDA and Sorrento Therapeutics have been going back and forth in a pre IND talks. During those talks the FDA gives guidance as to what they want to see upon IND submittal. Its like your professor proofreading your 1st and 2nd draft of a writing then asking you to make those changes. You make those changes and its an easy A. I hope I painted a picture that the IND will be approved. My hypothesis is that the trials will begin late August for STI-1499 'The Cure"
The third catalyst to be aware of is phase two trials of Abivertinib. I want to make this clear about this drug. It has already shown efficacy in a phase two lung cancer trial and currently ready to begin phase 3...
All the hype around this 30 minute saliva test took price action to the next level. It was like throwing gas on fire. I mean, Sorrento Therapeutics had a 24 dollar price target before this covid pipeline. Sorrento now has:
• COVI-TRACK™ (Antibody Test for the Detection of Antibodies to SARS-CoV-2 in blood)
• COVI-GUARD™ (Neutralizing Antibody – STI 1499)
• COVI-SHIELD™ (Neutralizing Antibody Cocktail)
• COVIDTRAP™ (ACE2 Receptor Decoy – STI 4398)
• T-VIVA-19™ (Vaccine)
• ABIVERTINIB (Cytokine Storm – STI5656)
• And now *COVI-TRACE™ (Diagnostic Test for the Detection of SARS-CoV-2 in Saliva)
in the Covid pipeline.”
This company has a great Covid Strategy. First two rapid accurate tests. Then the oral drug to calm the cytokine storm . Followed by safe and powerful antibodies to attack the virus. And finally 4 or 5 vaccine candidates to prevent infection. WHEN OTHERS FAIL THEY WILL BE THERE WITH "THE BEST-IN-CLASS " TO DOMINATE THE MARKET. Think how 93% effective Shingrex dominates the shingles market where the SOC was about 55% effective.
I'm not usually a Cramer fan but this is so true!
"... today I am reserving my wrath for the clueless buyers who are not only working at home, but have taken a permanent intellectual summer vacation.
I want to start with Sorrento Therapeutics (SRNE) , a company I have championed several times including, the beginning of June, when the stock was at $4 and management talked about how it is working on both prevention and cure of Covid and then again, several weeks ago, when the stock was $8 and the company seem to be making a ton of progress, far further along than a lot of the larger companies in the space despite its tiny billion dollar size. I thought this company had many shots on the Covid goal and should be bought by those who are looking for a speculative way to invest in an out of the way company doing great things. I had been skeptical, called Meg Terrill, our biotech expert to be sure I wasn't off-track, and then listened to Dr. Henry Ji, the co-founder, chairman and CEO of Sorrento and I liked everything I heard.
Sure enough, last Wednesday at 9 a.m., Sorrento announced it is licensing a rapid on-site detection test for Covid-19. The test, from Columbia University, gives you a positive or negative color change in 30 minutes or less after contact with a person's saliva. The almost totally foolproof test does not need to be shipped to a reference lab, the big bottleneck that is stymieing the nation, and must, privately, be driving the president crazy. The product, to be marketed by Sorrento and called Covi-Trace, holds everything in a single tube and can be done right now on site, but potentially can be done at home. Oh, and it doesn't require a swab jammed up your nose for 12 seconds, and that's 12 "one Mississippi ... two Mississippi" seconds, with 97% sensitivity for the positive rate and 100% specificity for the negative rate.
When I saw this I told my wife, Lisa, there it is, we're gonna get out of this darned thing whole because Sorrento figured it out. Of course, I then heard that she always wanted to go to Sorrento, a favorite town of opera great Enrico Caruso.
No, I said, I am talking about Sorrento Therapeutics. But the stock, at $8 and change, did nothing. No reaction? I guess it's phony. I guess Columbia University's work is slipshod or Sorrento's being too promotional.
Tuesday, on the exact same news as last Wednesday, Sorrento's stock vaulted to $12, a 21% gain, before pulling back, on more than one hundred million shares, extraordinary given that there are only 200 million shares.
How stupid is that?"
SORRENTO is going to be a very well known Covid-19 brand name.
Do you want to know if you've been exposed to the virus? Sorrento's 8 minute COVI-TRACK will tell you.
Do you want to know if you HAVE the virus? Sorrento's 30 minute COVI-TRACE will tell you.
Does your doctor want to clear the virus from your body? Sorrento's COVI-GUARD or COVI-SHIELD antibodies will do that.
Do your body need some help preventing a cytokine storm? Your doctor can prescribe Sorrento's oral Abivirtinib.
Do you need a longer lasting vaccine? Sorrento has 4 in development.
No other company, large or small, has as many shots on goal!
It's time start a go-fund-me site for shorts. #onlyfoolsshortSorrento .
Here's a great chart of Sorrento's Covid-19 portfolio...only Sorrento has 11 shots on goal.
https://charts.stocktwits.com/production/original_233312563.png
Great chart of Sorrento's Covid-19 portfolio
https://charts.stocktwits.com/production/original_233312563.png
Those who follow this stock closely know there's more news coming regarding the tests. Tuesday or Wednesday ?
I too wondered how an ambulance chasing lawfirm rated a sticky?
The 8 minute COVI-TRACK test has been assigned a registration number and will soon be approved. Here is more information from the Sorrento website.
https://sorrentotherapeutics.com/research/covid-19/covi-track/
AUGUST CATALYSTS for Sorrento? My quess is at least 75% will occur this month. What do you think?
1. COVI-TRACK 8 minute antibody test kit approval and marketing partnership
2. COVI-TRACE 30 minute virus saliva test kit approval
3. Celularity reports good interim phase 1/2 results (Sorrento owns 25%)
4. COVI-GUARD single antibody enters clinic
5. COVI-SHIELD triple antibody enters clinic
6. T-VIVA-19 vaccine enters clinic
7. Abivirtinib ARDS trial phase 2 enters clinic
8. Sorrento/SmartPharm antibody vaccine enters clinic
9. Federal grants $500+ million
10. PSS out-of-court settlement $1.2 billion
11. Any of half a dozen pain and cancer drug program announcements
12. Analysts upgrade from current $24 price target (DONE. Now $30 and rises as each catalyst is announced)
Highly accurate Columbia University 30 minute saliva test that SRNE licensed:
https://www.medrxiv.org/content/10.1101/2020.06.13.20129841v1.full.pdf
AUGUST CATALYSTS for Sorrento? My quess is at least 75% will be this month. What do you think?
1. COVI-TRACK 8 minute antibody test kit approval and marketing partnership
2. COVI-TRACE virus test kit approval
3. Celularity reports good interim phase 1/2 results (Sorrento owns 25%)
4. COVI-GUARD single antibody enters clinic
5. COVI-SHIELD triple antibody enters clinic
6. T-VIVA-19 vaccine enters clinic
7. Abivirtinib ARDS trial phase 2 enters clinic
8. Sorrento /SmartPharm antibody vaccine enters clinic
10. Federal grants $500+ million
11. PSS out-of-court settlement $1.2 billion
12. Any of half a dozen pain and cancer drug program announcements
13. Analysts upgrade from current $24 price target (DONE. Now $30 and rises as each catalyst is announced)
Next potential CATALYSTS for Sorrento? This week? Next week?
1. COVI-TRACK 8 minute antibody test kit approval and marketing partnership
2. COVI-TRACE virus test kit approval
3. Celularity reports good interim phase 1/2 results (Sorrento owns 25%)
4. COVI-GUARD single antibody enters clinic
5. COVI-SHIELD triple antibody enters clinic
6. T-VIVA-19 vaccine enters clinic
7. Abivirtinib ARDS trial phase 2 enters clinic
8. Sorrento /SmartPharm antibody vaccine enters clinic
10. Federal grants $500+ million
11. PSS out-of-court settlement $1.2 billion
12. Any of half a dozen pain and cancer drug program announcements
13. Analysts upgrade from current $24 price target (DONE now $30 and rises as each catalyst is announced)
WEBSITE UPDATED...
COVIDTRACK & COVIDTRACE listed
https://sorrentotherapeutics.com/research/pipeline/
Sorrento has several blockbuster drugs for pain and cancer. AND HAS ADDED AN EXCITING PORTFOLIO OF BLOCKBUSTER ANTI-COVID TECHNOLOGIES.
*Sorrento picks up color-changing COVID-19 saliva test built by Columbia University fertility clinic
* Sorrento ventures into COVID-19 with Mount Sinai antibody pact
* FDA to issues an EUA, the company said the COVI-TRACK test will be available for distribution to clinical testing sites nationwide. The company also said it has secured manufacturing capacity to produce up to 5 million test kits per month.
* STI-1499, named COVI-GUARD, which is being evaluated as a standalone antibody therapy aimed at blocking viral entry into host cells.
* COVI-SHIELD, a proprietary cocktail of therapeutic antibody, including STI-1499, focused on inhibiting viral infection of healthy host cells.
* A proprietary COVIDTRAP ACE2-Fc protein, which binds to the S1 domain of the spike protein of the SARS-CoV-2 virus, thereby blocking the virus from binding and infecting respiratory epithelial cells.
* A next-generation, gene-encoded antibody vaccine against COVID-19.The ACE-MAB fusion protein, which utilizes its STI-4920 antibody and Mabpharm Ltd.'s fusion protein CMAB020 to create a bispecific fusion protein with two functional arms.
* STI-6991, an I-Cell COVID-19 vaccine. A natural killer cell-based immunotherapy approach, named COVI-CELL, to treat critically and severely ill COVID-19 patients
* Abivertinib phase 2 to prevent and treat cytokine storm ARDS.(already proven safe in over 600 cancer patients.)
Here is some information and an opinion on the PSS lawsuit .
Case 19STCV11328 arbitration in the case of Sorrento v NantPharma is ongoing.. with a status hearing on 8/12. Pending arbitration must be settled before the consolidated case 20STCV08789 Sorrento v Patrick Soon Shiong for common law fraud will be heard. Consolidated case has been assigned a hearing date of 2/17/2022. Sorrento at its option can pursue a jury trial against PSS under 20STCV08789 if arbitration doesn't resolve by the February hearing date.
Here is another posters analysis
"I'm wishing I can attend the trial. What's Shiong gonna say? That he was a "babe in the woods" and thought Sorrento's Cynvilocq was "good" but it turned out to be "bad"? Really? The inventor of Abraxane, a world class expert on that type of drug, had no clue about what he was buying into???!!!
Not to mention that now-patent-UNprotected Cynvilcq (due to Shiong having allowed patents to expire) is being sold in South Korea and is well known to be a safe and efficacious cancer drug?
Seems like the Shiong legal team will have to pull a rabbit out of a hat to have a chance in this litigation."
Stay classy San Diego! interview: The saliva test is easy, convenient, and cheap. the company can make 100 Million tests per month. A game changer!!! the company will submit to FDA for approval mid or later August.
https://www.kusi.com/sorrento-therapeutics-announces-rapid-covid-19-diagnostic-saliva-test-with-30-minute-results/